BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has scheduled its second quarter 2025 financial results conference call for Tuesday, August 5, 2025, at 4:30 pm ET. The company will release its financial results and business updates after market close on the same day.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will be available for 30 days following the event.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica specializzata in malattie genetiche, ha programmato la sua conferenza telefonica sui risultati finanziari del secondo trimestre 2025 per martedì 5 agosto 2025, alle 16:30 ET. La società pubblicherà i risultati finanziari e gli aggiornamenti aziendali dopo la chiusura del mercato lo stesso giorno.
Investitori e soggetti interessati potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di BridgeBio. La registrazione sarà disponibile per 30 giorni dopo l’evento.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica especializada en enfermedades genéticas, ha programado su conferencia telefónica de resultados financieros del segundo trimestre de 2025 para el martes 5 de agosto de 2025, a las 4:30 pm ET. La empresa publicará sus resultados financieros y actualizaciones comerciales después del cierre del mercado ese mismo día.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de BridgeBio. La repetición estará disponible durante 30 días después del evento.
BridgeBio Pharma (나스닥: BBIO)는 유전 질환을 전문으로 하는 바이오제약 회사로, 2025년 2분기 재무 실적 컨퍼런스 콜을 2025년 8월 5일 화요일 오후 4시 30분(동부시간)에 개최할 예정입니다. 회사는 같은 날 시장 마감 후 재무 실적 및 사업 업데이트를 발표할 예정입니다.
투자자 및 관심 있는 분들은 BridgeBio 투자자 관계 웹사이트를 통해 실시간 웹캐스트에 접속할 수 있습니다. 행사가 끝난 후 30일 동안 다시보기 서비스도 제공됩니다.
BridgeBio Pharma (Nasdaq : BBIO), une société biopharmaceutique spécialisée dans les maladies génétiques, a programmé sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 pour le mardi 5 août 2025 à 16h30 ET. L'entreprise publiera ses résultats financiers et ses mises à jour commerciales après la clôture du marché le même jour.
Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via le site web des relations investisseurs de BridgeBio. Une rediffusion sera disponible pendant 30 jours après l'événement.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen, das sich auf genetische Erkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 für Dienstag, den 5. August 2025, um 16:30 Uhr ET angesetzt. Das Unternehmen wird seine Finanzergebnisse und Geschäftsaktualisierungen am selben Tag nach Börsenschluss veröffentlichen.
Investoren und Interessierte können den Live-Webcast über die Investor-Relations-Website von BridgeBio verfolgen. Eine Aufzeichnung steht 30 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/951604231.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When will BridgeBio (BBIO) report Q2 2025 earnings?
How can I access BridgeBio's Q2 2025 earnings call?
How long will BridgeBio's Q2 2025 earnings call replay be available?
What is BridgeBio's stock symbol?
